Publications
iScienceApr 2023 |
26
(
4
),
106345
DOI:
10.1016/j.isci.2023.106345

Changes in serum-neutralizing antibody potency and breadth post-SARS-CoV-2 mRNA vaccine boost

Nair, Manoj S; Ribeiro, Ruy M; Wang, Maple; Bowen, Anthony D; Liu, Lihong; Guo, Yicheng; Chang, Jennifer Y; Wang, Pengfei; Sheng, Zizhang; Sobieszczyk, Magdalena E; Perelson, Alan S; Huang, Yaoxing; Ho, David D
Product Used
Genes
Abstract
A better understanding of the durability and breadth of serum-neutralizing antibody responses against multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants elicited by COVID-19 vaccines is crucial in addressing the current pandemic. In this study, we quantified the decay of serum neutralization antibodies (nAbs) after second and third doses of the original COVID-19 mRNA vaccine. Using an authentic virus-neutralization assay, we found that decay half-lives of WA1- and Delta-nAbs were both ∼60 days after second and third vaccine dose. Unexpectedly, the durability of serum antibodies that neutralize three different Omicron subvariants (BA.1.1, BA.5, BA.2.12.1) was substantially better, with half-lives of ≥6 months. A booster dose of the original COVID-19 vaccine was also found to broaden antibody responses against SARS-CoV and four other sarbecoviruses, in addition to multiple SARS-CoV-2 strains. These findings suggest that repeated vaccinations with the COVID-19 vaccine may confer a degree of protection against future spillover of sarbecoviruses from animal reservoirs.
Product Used
Genes

Related Publications